Latest news

Thumbnail image for Roche’s Erivedge no longer funded by the NHS

Roche’s Erivedge no longer funded by the NHS

Roche’s Erivedge will indeed no longer be funded on the National Health Service as a treatment for skin cancer after cost regulators issued final guidance ruling that it is not cost effective.

23rd November 2017

Thumbnail image for Health/industry groups react to Autumn Budget

Health/industry groups react to Autumn Budget

Chancellor Philip Hammond’s Autumn Budget has promised an extra £2.8 billion for NHS services over the next three years, though the amount falls well short of the £4 billion deemed by health leaders as necessary to retain the current quality of services.

23rd November 2017

Thumbnail image for EU approves post-chemo option for patients with ovarian cancer

EU approves post-chemo option for patients with ovarian cancer

European regulators have cleared Tesaro’s Zejula, offering a new option for the maintenance treatment of certain adults with platinum-sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer.

22nd November 2017

Thumbnail image for EU nod for opioid dependence therapy

EU nod for opioid dependence therapy

The European Medicines Agency has issued a marketing authorisation for Orexo and MundiPharma’s Zubsolv (buprenorphine and naloxone) for opioid dependence.

21st November 2017

Previous  --   8 9 10 11 12 13 14 15 16 17   --  Next

Download our apps

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Download